Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin alpha5beta1 (EC50=0.2 nM). Integrin alpha5beta1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs)[1][2].
Molecular Weight:
(145.5 kDa)
Purity:
99.96
CAS Number:
[558480-40-3]
Target:
Integrin
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
